BPC-157 / TB-500 Blend Research Guide: Identity, Literature, Analysis and Documentation
Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.
This product is two peptides in one vial: BPC-157, a 15-residue sequence, and TB-500, the acetylated seven-residue fragment of thymosin beta-4. They are the two compounds that appear together most often in preclinical tissue-repair literature, which is why they are sold as a pair. This page gives the identity of both, the research areas each literature covers, what a two-component certificate should show, and the report on file for StarBio’s lot.
Identity
| Name | BPC-157 / TB-500 blend |
|---|---|
| Type | Two-peptide research blend in one lyophilized vial |
| Component 1 | BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, 1419.54 g/mol, CAS 137525-51-0 |
| Component 2 | TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, 889.02 g/mol, CAS 885340-08-9 |
| Labelled total | 10 mg or 20 mg, in equal nominal amounts |
Origin and history
BPC-157 was described in the early 1990s by Predrag Sikiric’s group in Zagreb as a fragment of a protein isolated from gastric juice, and nearly all of its literature still comes from that school. Thymosin beta-4 was isolated and sequenced in 1981 in Allan Goldstein’s laboratory, from a thymus preparation his group had studied since the 1960s, and was later shown to be the main actin-sequestering protein of most cells. TB-500 is its residues 17 to 23 with an acetylated N-terminus, the short segment that binds actin. The pairing is a catalogue product. No study on file examines the two together.
What the literature covers
The references on file for this compound span several research areas. They are listed here as areas of study, not as results.
- BPC-157. A tendon cell study (2011) [3], vascular signalling in rats (2020) [5], pharmacokinetics and preclinical safety in rats and dogs (2020, 2022) [7, 9], a brain-gut axis review (2016) [11] and a 2025 systematic review [1].
- Thymosin beta-4. Reviews of its properties (2012) [2], animal studies (2010) [4], dermal work (2016) [10], ocular research (2018, 2023) [6, 12] and a 2023 review [8].
The thymosin beta-4 papers describe the full 43-residue protein. They say little about the seven-residue fragment as a material beyond its origin.
Analytical notes
A certificate for this blend should show two main peaks, well separated by the difference in size and hydrophobicity: TB-500 at 889 Da elutes first, BPC-157 at 1419.5 Da later. The mass spectrum should confirm both, with the acetyl group on TB-500 adding 42 Da over the free heptapeptide. The purity figure is the combined area of the two expected peaks. It does not show the ratio between them, so measured content per component is the more informative figure wherever a laboratory reports it.
Neither sequence contains methionine, cysteine or tryptophan, so both are comparatively stable to oxidation. BPC-157 has two adjacent aspartic acid residues, which makes it acidic, while TB-500 with two lysines is basic. In a shared solution that difference matters little, but it does mean the two respond differently to a change of mobile-phase pH, which is useful to an analyst trying to move one peak without the other.
Storage and stability
- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term
Documentation for StarBio lots
Every StarBio lot is analysed by an independent laboratory. The table lists the report on file for this compound.
| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested | |
|---|---|---|---|---|---|
| BPC-157 / TB-500 10 mg | Medutest WWB-BB10-9123 | 99.07% | 10 mg | Feb 20, 2026 | report |
Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.
References
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal (NIH/PubMed Central), 2025, PMID 40756949.
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert opinion on biological therapy, 2012, PMID 22074294.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011, PMID 21030672.
- Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010, PMID 20536453.
- Modulatory effects of BPC 157 on vasomotor tone and the Src-Cav-1-eNOS signaling pathway in rats. Scientific Reports (Nature), 2020, PMID 33046803.
- Thymosin beta 4 and the eye: the journey from bench to bedside. Expert opinion on biological therapy, 2018, PMID 30063853.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022.
- Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. International immunopharmacology, 2023, PMID 36709593.
- Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020, PMID 32334036.
- Thymosin β4 Promotes Dermal Healing. Vitamins and hormones, 2016, PMID 27450738.
- Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology, 2016, PMID 27138887.
- Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis. International immunopharmacology, 2023, PMID 37018981.
Product page: BPC-157 / TB-500 Blend. Related guides: BPC-157 research guide, TB-500 research guide, GLOW research guide, what 99% purity means, storing lyophilized peptides.
For laboratory research use only. Not for human or veterinary use.
Questions about BPC-157 / TB-500 Blend
What is BPC-157 / TB-500 Blend?
BPC-157 / TB-500 Blend is a peptide blend (BPC-157 + TB-500). It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.
Is BPC-157 / TB-500 Blend the same as BPC-157 and TB-500 blend?
BPC-157 / TB-500 Blend is also listed as BPC-157 and TB-500 blend. On a certificate or vial label, the sequence identify the material regardless of which name is used.
Is StarBio's BPC-157 / TB-500 Blend independently tested?
Yes. The current BPC-157 / TB-500 Blend batch was tested by Medutest (Medutest report WWB-BB10-9123): 99.07% purity by HPLC, tested Feb 20, 2026. The report is on file in the COA library (report page).
How should BPC-157 / TB-500 Blend be stored?
Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.
Where can I buy BPC-157 / TB-500 Blend for laboratory research?
StarBio sells BPC-157 / TB-500 Blend as 10 mg at $79.99 and 20 mg at $149.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.
New reports and guides, by email
A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.
For laboratory research use only. No dosing or protocol content is ever sent.

